Don't Overlook The Risks Of Innovative Clinical Trials
Source: Life Science Leader
By Nathalie Smyth, Daniel Brettler, Michele Fields, & Camille Hepsworth
The clinical trials landscape is evolving at an unprecedented pace, being both propelled and incentivized by the global race to advance the COVID-19 vaccines. Advancements in AI and machine learning (ML) for data collection and interpretation and a move toward virtual and adaptive trials and use of real-world data (RWD) have paved the way for the development of novel data collection techniques and analysis. These advancements also could increase the threat of cyberattacks and malicious hacking of private medical data.
VIEW THE MAGAZINE ARTICLE!
Log In
Signing up provides unlimited access to:
Free Sign Up

Signing up provides unlimited access to:
- Trend and Leadership Articles
- Case Studies
- Extensive Product Database
- Premium Content
HELLO. PLEASE LOG IN.
X
Not yet a member of Life Science Leader? Register today.
ACCOUNT SIGN UP
X
Please fill in your account details
ACCOUNT SIGN UP
This website uses cookies to ensure you get the best experience on our website. Learn more